By Fineline Cube 
Dr. Cheng Kam-chung, Founder and Chairman of the Greater China Cancer Foundation (GCCF), led a delegation to visit Chia Tai Tianqing Pharmaceutical Group (CTTQ) to explore collaboration opportunities in bringing mainland China-developed innovative drugs to Hong Kong.
Objective of the Visit
The visit focused on discussing the current progress of the Named Patient Program (NPP) in Hong Kong and future expansion plans for patient access initiatives. The goal is to address medication access challenges in Hong Kong by introducing high-quality, innovative anti-cancer drugs from mainland China.
Desired Outcomes
The collaboration aims to help alleviate the difficulties of “limited drug availability and high treatment costs” faced by local patients.-Fineline Info & Tech